In oncology, understanding the mechanisms behind the spread of cancer cells through blood and lymphatic vessels is crucial ...

The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.

PLEK2 has been found to promote the progression and metastasis of some tumors, but its role in UVM has not yet been reported. Through this study, we hope to explore the effect of PLEK2 on the ...

Indoor tanning exposure was not found to be correlated with melanoma tumor mutational burden, unlike age, nonmelanoma skin ...

The Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for patients with locally advanced or ...

The world's oceans represent a vast and largely untapped source of biodiversity, offering a high probability for the ...

CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical ...

The CAIRO5 trial confirmed the benefit of both two-drug chemotherapy regimens with bevacizumab instead of a three-drug ...

Deep learning models show remarkable results in automated skin lesion analysis. However, these models demand considerable amounts of data, while the availability of annotated skin lesion images is ...

Immunotherapy is the brightest new weapon in fight against cancer. Thank Dr. Steven Rosenberg, who 40 years ago successfully ...

all patients developing positive DTH reactions had a clinical response of complete or partial rejection of metastatic lesions. Patient 2, who did not develop a positive skin reaction after ...